SpyGlass Pharma Announces Acquisition of Advanced Vision Science for $13M

What Happened SpyGlass Pharma, Inc. announced on October 1, 2026 that it closed a Stock Purchase Agreement to acquire 100% of Advanced Vision Science, Inc. (AVS) from Santen Holdings US, Inc. The aggregate consideration was based on a $13,000,000 purchase price, estimated at closing and subject to customary post‑closing adjustments. The Company furnished a related press release under Regulation FD as Exhibit 99.1.

Key Details

• Closing date: October 1, 2026; Seller: Santen Holdings US, Inc.; Parent guarantor: Santen Pharmaceutical Co., Ltd.
• Purchase price: $13,000,000 (estimated at Closing and subject to customary post‑Closing adjustment).
• AVS was SpyGlass’s supplier of intraocular lenses prior to the Acquisition and will continue manufacturing Eternity‑brand IOLs.
• AVS and Parent executed an Amended and Restated Supply & Distribution Agreement (Parent granted exclusive rights to sell these products in Japan) and reciprocal non‑exclusive cross‑license agreements; Parent guaranteed Seller’s obligations under the Purchase Agreement.

Why It Matters The deal brings SpyGlass’s former supplier (AVS) into the company, which could affect control over product supply and operations for its intraocular lens business. The filing provides concrete purchase price and contractual details (supply, distribution, cross‑licenses, and Parent guarantee) but does not disclose expected revenue impact, cost synergies, or financing arrangements. Investors should note the purchase price is estimated and subject to post‑closing adjustment and review any future disclosures for financial effects.